Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 11/20 | 0.37 |
| ▸ | P2RX2 | Q9UBL9 | 11/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29214464 | 0.83 | NOS3 (0.34) | NOS3NOS1NOS2DHFR | |
| SCHEMBL29910000 | 0.80 | GABRA1 (0.38) | NOS3NOS1NOS2P2RX3P2RX2 | |
| SCHEMBL2737356 | 0.80 | NOS3 (0.56) | NOS3NOS1NOS2P2RX3P2RX2 | |
| SCHEMBL17953260 | 0.80 | GABRA1 (0.38) | NOS3NOS1NOS2P2RX3P2RX2 | |
| SCHEMBL23434930 | 0.78 | GABRA1 (0.43) | NOS3NOS1NOS2P2RX3P2RX2 | |
| SCHEMBL31145117 | 0.78 | KMT2A (0.54) | NOS3NOS1NOS2P2RX3P2RX2 | |
| SCHEMBL19880443 | 0.78 | P2RX3 (0.35) | NOS3NOS1NOS2P2RX3P2RX2 | |
| SCHEMBL12191685 | 0.78 | JAK2 (0.38) | NOS3NOS1NOS2P2RX3P2RX2 | |
| SCHEMBL29347856 | 0.78 | KMT2A (0.54) | NOS3NOS1NOS2P2RX3P2RX2 | |
| SCHEMBL115578 | 0.75 | PIK3R1 (0.40) | P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4725282-A | LOW VISCOSITY; STORAGE STABILITY | WELLA AKTIENGESELLSCHAFT (DE) | 1988-02-16 | — | — | US | claimed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| CN-111868037-B | Fused cyclic urea derivatives as CRHR2 antagonists | 拉夸里亚创药株式会社 | 2023-10-13 | — | — | CN | disclosed |
| EP-3774739-B1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2021-03-18 | — | — | US | disclosed |
| EP-3774739-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RaQualia Pharma Inc. (JP) | 2021-02-17 | — | — | EP | disclosed |
| CN-111868037-A | Fused cyclic urea derivatives as CRHR2 antagonists | 拉夸里亚创药株式会社 | 2020-10-30 | — | — | CN | disclosed |
| WO-2019198692-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2019-10-17 | — | — | WO | disclosed |
| EP-1831198-B1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| US-4725282-A | LOW VISCOSITY; STORAGE STABILITY | WELLA AKTIENGESELLSCHAFT (DE) | 1988-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | CRHR2, CRHR1, CRH | NOS3 1614/4885NOS1 2176/4885NOS2 1129/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | NOS3 1614/4885NOS1 2176/4885NOS2 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.